patients were treated with concurrent chemoradiation followed by brachytherapy. The median follow-up period was 47 months. The three-year DFS and OS were 13.3% and 13.3% respectively.

Conclusion CCCC has a poor prognosis, stage for stage compared to other histologies. The FIGO stage, tumour size, lymphovascular space invasion and pelvic node status were factors that predicted the prognosis. Adjuvant radiotherapy or chemoradiotherapy have a limited role in the treatment of this rare cancer.

Disclosures The authors have no potential conflict of interest to disclose.

285 EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV+ WOMEN OLDER THAN 40 YEARS: SUB-ANALYSIS OF PALOMA CLINICAL TRIAL

Yann Gaslain, 1Luis Serrano, 2Andrés Carlos López, 2Sílvia González, 2Santiago Palacios, 1Damian Dexeus, 2Pluvio Coronado, Jesús de la Fuente, 3José Antonio López, 3Cristina Vanrell, 1Procare Health; 2Centro Médico Gabinete Velázquez; 3Hospital Quironsalud; 4Instituto Palacios Salud Y Medicina de la Mujer; 5Women’s Health Institute; 6Hospital Clínico San Carlos; 7Hospital Universitario Infantia Leonor; 8Hospital General Universitario de Alcante; 9Hospital de la Santa Creu i Sant Pau

Methodology Paloma clinical trial (Clinical Trials.gov NCT04002154) was a multicenter, randomized, open-label, parallel-group, usual practice-controlled clinical trial. Unvaccinated HPV positive women aged between 30–65 with cytology of ASCUS or LSIL and concordant colposcopic image were randomized into 3 groups: A) Papilocare® 1 cannula/day for 1 month + 1 cannula/alternate days for 5 months; B) Papilocare® 1 cannula/day for 3 months + 1 cannula/alternate days for 3 months; C) Control group: no treatment (usual clinical practice). Primary endpoint: % of patients with normal cytology and concordant colposcopy after 6 months of treatment in the total population, high-risk HPV (16,18,31,33,35,39,45,51,52,56,58,59,68) and very high-risk HPV , respectively. At 6 months, normal cytology and concordant colposcopy image was observed in 92%, 90% and 79% of patients treated with Papilocare® vs 50%, 33% and 40% of patients in control group, in the total population, and high-risk and 16-18-31 subpopulations (p=0.0066; p=0.0031; p=0.2929, Fisher test) respectively.

Conclusion Papilocare® showed a robust efficacy in normalizing cervical HPV lesions in women older than 40 years old, with a statistically significant difference vs control group in the total and high-risk populations.


All other authors have declared no conflicts of interest.

287 REAL-LIFE EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV PATIENTS: INTERIM ANALYSIS

Yann Gaslain, 1Javier Cortés, 2Javier de Santiago, 3María Pilar Sanjuán, 4Marta Ageroño, 2Gabriel Fiol, 4Carmen García, 3Marta Gurea, 4Perla Hernández. 1Procare Health; 2Private Practice; 3Centro Oncológico MD Anderson; 4Clínica Ginemed; 5Hospital Sanitas La Zarzuela; 6Hem San Francisco; 7Hospital La Fe

Introduction/Background Real-life studies inform on the ‘effectiveness’ of a treatment what is intended to do in routine circumstances. The aim of this study is to evaluate the efficacy of Papilocare® - a multi-ingredient Coriolus versicolor-based vaginal gel- on repairing high-risk (HR) HPV-dependent low-degree cervical lesions and HR-HPV clearance in real-life practice.

Methodology Observational, multicenter, prospective, one-cohort study (PAPILOBS study ClinicalTrial.gov: NCT04199260). Currently recruiting 300 vaccinated or not HPV-positive women aged > 25y with Pap smear of ASCUS or LSIL and concordant colposcopy during routine clinical visits in Spain. Patients are treated with Papilocare® 1 cannula/day for 21 days the first month + 1 cannula/alternate days for 5 months. After this 6-month period, patients with altered cytology and/or HPV persistency are treated for a 6-month extension treatment period with the same dosage.

Interim analysis of HR-HPV patients with normal Pap smear and concordant colposcopy image (primary endpoint) and patient with HR-HPV cleared (patients with total clearance or partial clearance together with negative Pap smear and normal colposcopy) at 6/12 months is presented. The study was approved by the ethical committee of Public University Hospital of Puerta de Hierro (Madrid). Informed consent was signed by all patients.

Results At 6 months, data of 148 and 146 patients for Pap smear/colposcopy and HR-HPV presence, respectively, were available. 67.6% of patients (100/148) had negative Pap smear and concordant colposcopy. HR-HPV clearance was observed in 58.9% of patients (86/146). Data of 46 and 44 patients included in the 6-month extension treatment period for Pap smear/colposcopy and HR-HPV presence, respectively, were available. At 12 months, 78.3% (36/46) of patients had negative Pap smear and concordant colposcopy and HR-HPV clearance was observed in 70.5% (31/44). Considering all study period, 77% (114/148) and 72.6% (106/146) of patients repaired HR-HPV-dependent cervical lesions and cleared HR-HPV, respectively.

Conclusion In this interim analysis, repairing of HR-HPV-dependent low-degree cervical lesions and clearing HR-HPV, in real life conditions, was achieved after 6-month treatment.
with Papilocare® (or extending it up to 12-months if needed) in 3 out of 4 patients. These findings need to be confirmed upon study completion.

Disclosures Funding: Procure Health Disclosure: J.Cortés: Advisory/Consulting Role and Speaker at Procure Health. Y.Gaslain: CEO of Procure Health. All other authors have declared no conflicts of interest.

Introduction/Background To evaluate the consistency of the efficacy of a non-hormonal multi-ingredient Coriolus versicolor-based vaginal gel, Papilocare®, on HPV clearance in patients infected by high-risk HPV (HR-HPV) in several studies.

Methodology Results at 6 months from independent observational non-comparative studies carried out in three different public centers and in a one private center were compared to results from both a randomized, open, parallel and controlled clinical trial comparing the Papilocare® vs wait and see approach (The Paloma RCT) and a observational, multicenter, prospective, one-cohort study (Papilobs real-life study). Two prospective (Vigo and Bari studies) and two retrospective studies (Coruña and Hospitala studies) have been performed.

Vigo study: HPV clearance of 25 patients infected by HPV 16 and/or 18 was evaluated as a secondary endpoint.

Bari study: HPV clearance of 98 HR-HPV patients was evaluated as primary endpoint.

Coruña study: 57 medical records of patients with HR-HPV were analyzed. HPV clearance was evaluated as primary endpoint.

Hospitala study: Data of 91 HR-HPV patients were evaluated. Primary endpoint: composite efficacy variable (percentage of patients with normal cytology and/or HPV clearance).

Papilobs study: Interim data of 148 HR-HPV patients is presented. HR-HPV clearance was evaluated as secondary endpoint.

Paloma RCT: 66 HR-HPV patients were evaluated. Percentage of patients with HR-HPV clearance was assessed as a secondary endpoint.

Results After the 6-month treatment period, 48% and 57% of patients cleared HPV 16–18 and HR-HPV in Vigo and Bari studies, respectively. A reduction of 58% was observed in number of HR-HPV patients (Coruña) and 72.5% of patients negativated cytology and/or cleared HR-HPV (Hospitala) (p≤0.0001 vs baseline for all results, Chi-square). In the Paloma RCT, HR-HPV clearance was observed in 63% of patients treated with Papilocare® vs 40% in the control group. Similar rate of 59% HR-HPV clearance was observed in the interim analysis of the Papilobs study.

Conclusion Papilocare® has shown significant and consistent rates of HR-HPV clearance ranging from 50% to 70% in the 6 different studies. This high consistently rate of HR-HPV clearance should be further confirmed in ongoing studies.

Disclosures Funding: Procure Health. Disclosures: J.Cortés, S. Palacios, D. Dexeus, L. Serrano: Advisory/Consulting Role and Speakers at Procure Health. Y.Gaslain: CEO of Procure Health. All other authors have declared no conflicts of interest.

Introduction/Background A number of targeted antibody drug conjugates (ADCs) are emerging with the potential to become important new treatment strategies for gynecological cancers, including recurrent/resistant ovarian and cervical cancers. This study determined whether online continuing medical education could improve the knowledge of oncologists and obstetricians/gynaecologists (obs/gyns) on the rationale and evidence for emerging ADCs.

Methodology A 30-minute online video lecture was launched for physicians outside the USA in December 2019. Data was collected to March 2020. Educational effect assessed with repeated-pairs pre-/post-activity, where individual participants served as their own control. 3 multiple-choice, knowledge questions and 1 self-efficacy, 5-point Likert scale confidence question were analyzed. Chi-squared test assessed pre- to post-activity change (5% significance level, P <.05). Magnitude of change in total number of correct responses overall, and for each question, were determined with Cramer’s V (<.06=Modest, 0.06–.15=Noticeable, .16–.26=Considerable, >.26=Extensive).

Results 49 oncologists and 154 obs/gyns completed pre- and post-activity questions. A positive educational effect was observed for oncologists (considerable effect, V=.217, P=.0002) and obs/gyns (noticeable effect, V=.097, p=.0028) with average% of correct responses increasing 40 to 62% for oncologists and 34 to 43%, for obs/gyns. Participants with 3/3 answers correct increased from pre- to post-activity (6 to 35%) for oncologists (considerable effect, V=.217, P=.0002) and obs/gyns (noticeable effect, V=.097, p=.0028). Improvements in % of correct responses post-activity were seen for all 3 knowledge-based questions on antigen targets, and key trial data for tisotumab vedotin and mirvetuximab vedotin (88%, 39%, 45% improvements for oncologists; 70%, 15%, 16% improvements for obs/gyns). Confidence in knowledge of ADCs also improved post-activity with a total average confidence shift of 38% for oncologists and 32% for obs/gyns. 62% of oncologists’ and 44% of obs/gyns’ responses were reinforced or improved post-activity. 34% of all participants stated they would modify treatment plans as a result of participation in the activity.

Conclusion This on-demand, online video lecture resulted in a positive education effect for both oncologists and obs/gyns. However, persistent knowledge gaps are evident, especially amongst obs/gyns, suggesting there is a need for additional education as data on ADCs continues to emerge. Online medical education is valuable in establishing improved knowledge